Industry News Eli Lilly / Calytrix Bio BioPharma Dive
Lilly's 15th Buyout of 2026: $1.5B for Calytrix's CALR Antibody
- Lilly will pay up to $1.5B for Calytrix Bio, with an undisclosed upfront and milestones tied to clinical and regulatory goals.
- Calytrix is developing a biparatopic antibody against a cell-surface protein in CALR-mutant disease, aimed at myelofibrosis and essential thrombocythemia.
- It is Lilly's 15th announced acquisition this year, over $30B in total, mostly of private startups.
Mutant-CALR targeting is the prize in myeloproliferative neoplasms: JAK inhibitors like Jakafi manage symptoms but don't go after the clone. Lilly is again buying early and cheaply, so the price is an option on unproven biology rather than on data. The undisclosed stage and upfront make it hard to judge; the key test is whether the antibody can spare normal cells while clearing mutant ones.
Source: BioPharma Dive ↗ Lilly adds to buyout streak with $1.5B purchase of startup Calytrix